Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer

Binotto, Monique; Reinert, Tomás; Werutsky, Gustavo; Zaffaroni, Facundo; Schwartsmann, Gilberto

doi:10.3332/ecancer.2020.1007

Cited by 47 publications

(46 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, there are no studies in the literature evaluating long-term QoL in de novo stage IV BC patients who have undergone primary tumor surgery. QoL scores of BC survivors are worse in early treatment periods when STs are intense [29][30][31][32]48]. In fact, in a Chinese study where patients received six cycles of CT for BC, the fourth and fifth cycles of CT reported to show the most negative effect on QoL [49].…”

Section: Discussionmentioning

confidence: 99%

“…While state of health, financial income, and social support are other factors contributing to QoL, the most important of all is the burden created by the treatment modality applied such as surgery, chemotherapy (CT), radiation treatment (RT), and hormonal modalities [26][27][28][29][30][31][32][33][34][35]. Since stage IV BC patients receive life-long ST, the effects of treatment modalities become more prominent.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q

Soran

Soyder

Özbaş

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Background/objective Since more solid evidence has emerged supporting the effectiveness of loco-regional treatment (LRT), clinicians consider LRT a treatment option for selected de novo stage IV breast cancer (BC) patients. This is the first report on long-term quality of life (QoL) in a cohort of patients who were randomized to receive either LRT and then systemic treatment (ST) or ST alone in the protocol MF07-01. We aimed to evaluate QoL in patients living at least 3 years since randomization using scores from the SF-12 health survey. Methods SF-12 (V2) forms were completed during visits of patients who were living 36 months after the randomization. We first calculated PCS-12 (Physical Health Composite Scale) and MCS-12 (Mental Health Composite Scale) scores from de novo stage IV BC patients and compared them with the scores of patients diagnosed with stage I-III BC who lived more than 3 years. Further, PCS-12 and MCS-12 scores were compared between the LRT and ST groups with de novo stage IV BC. Additionally, general health, physical functioning, role functioning, bodily pain, vitality, mental health, and social functioning were evaluated and compared between the groups. Considering age-related changes in QoL, we also compared PCS-12 and MCS-12 scores of patients below or above 55 and 65 years of age. Responses to four additional questions (compare your physical health, mental health, daily activities, and energy currently vs. at diagnosis of BC) were recorded, considering cultural differences.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q

Soran

Soyder

Özbaş

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The quality of life is defined as a sense of well-being and includes physical, psychological, social, and spiritual aspects, which may be changed in cancer patients [6]. The quality of life of cancer patients is significantly reduced [7][8][9], which results from the disease process itself-its course, symptoms and complications, the applied treatment, and the disease duration [10].…”

Section: Introductionmentioning

confidence: 99%

Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials

et al. 2021

View full text Add to dashboard Cite

Most studies confirm the beneficial effects of enteral nutrition on the quality of life, but some studies indicate an inverse association and its detrimental impacts. However, there are insufficient data on the effects of enteral nutrition on the quality of life of cancer patients. This systematic review aimed to describe the influence of applied enteral nutrition on the quality of life of cancer patients, based on the results of randomized controlled trials. It was registered in the PROSPERO database (CRD42021261226) and conducted based on the PRISMA guidelines. The searching procedure was conducted using the PubMed and Web of Science databases, as well as Cochrane Library, and it included studies published until June 2021. It was conducted to select randomized controlled trials assessing the influence of enteral nutrition (compared with the other model of nutrition) on the quality of life of cancer patients. A general number of 761 records were screened and a final number of 16 studies were included in the systematic review. The studies were included and assessed by two independent researchers, while the risk of bias was analyzed using the Newcastle–Ottawa Scale (NOS). Studies compared patients treated with and without enteral nutrition, patients treated with various methods of enteral nutrition or with enteral diets of various content, as well as patients treated with enteral and parenteral nutrition. Within the included studies, the majority were conducted in patients with cancers located in various parts of the body, or diverse areas within the gastrointestinal system, while some studies were conducted in specific populations of patients with a defined cancer location—esophagus, stomach, or ovary. The duration of applied enteral nutrition within the included studies was diversified—from two weeks or less to half a year or even more. The vast majority of studies used well-known and validated tools to assess the quality of life, either developed for a specific group of head/neck, esophagus/stomach, and ovary cancer patients or developed for more general patient populations. Most studies concerning patients treated with and without enteral nutrition supported applying enteral nutrition, which was concluded in seven studies out of ten (including four studies with a low risk of bias). The other important observations to be emphasized—formulated based on the studies with a low risk of bias—presented the role of oral supportive nutrition guided by a dietitian, as well as the beneficial role of enteral and parenteral nutrition, combined. In spite of a relatively low number of randomized controlled trials assessing the influence of enteral nutrition on the quality of life of cancer patients, which should be considered as a limitation, the results were promising. Most studies supported the positive influence of enteral nutrition on the quality of life, either assessed based on the psychological measures of the quality of life or by considering the other potential determinants (e.g., malnutrition, complications, etc.). Taking this into account, enteral nutrition should be applied whenever possible, both to prevent and treat malnutrition in cancer patients. However, considering the limited number of studies conducted so far, further research conducted in homogenic populations of patients is necessary.

show abstract

“…Five decades later, despite ground-breaking discoveries and advancements in the field of cancer systems biology, a definitive and affordable cure for all types of cancer still evades humankind ( 2 ). Numerous “breakthrough” treatments have also gone on to exhibit adverse side effects ( 3 , 4 ) that lower patients’ quality of life (QoL) or have reported degrading efficacies ( 5 ). At the heart of this problem lies our limited understanding of the bewildering multifactorial biomolecular complexity as well as patient-centricity of cancer.…”

Section: Introductionmentioning

confidence: 99%

Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics

Gondal

Chaudhary

2021

Front. Oncol.

View full text Add to dashboard Cite

Rapid advancements in high-throughput omics technologies and experimental protocols have led to the generation of vast amounts of scale-specific biomolecular data on cancer that now populates several online databases and resources. Cancer systems biology models built using this data have the potential to provide specific insights into complex multifactorial aberrations underpinning tumor initiation, development, and metastasis. Furthermore, the annotation of these single- and multi-scale models with patient data can additionally assist in designing personalized therapeutic interventions as well as aid in clinical decision-making. Here, we have systematically reviewed the emergence and evolution of (i) repositories with scale-specific and multi-scale biomolecular cancer data, (ii) systems biology models developed using this data, (iii) associated simulation software for the development of personalized cancer therapeutics, and (iv) translational attempts to pipeline multi-scale panomics data for data-driven in silico clinical oncology. The review concludes that the absence of a generic, zero-code, panomics-based multi-scale modeling pipeline and associated software framework, impedes the development and seamless deployment of personalized in silico multi-scale models in clinical settings.

show abstract

Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer

Cited by 47 publications

References 31 publications

The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q

The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q

Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials

Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics

Contact Info

Product

Resources

About